Trevi Therapeutics (TRVI) announced that it has commenced an underwritten public offering of $100M of shares of its common stock. All of the shares in the offering are being offered by Trevi. Morgan Stanley, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
- Trevi Therapeutics Reports Positive Phase 2b Trial Results
- Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio
- Trevi Therapeutics’ Strong Market Potential and Revenue Opportunities Highlighted in Buy Rating
- Trevi Therapeutics initiated with a Buy at H.C. Wainwright